Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULARGeneric

ABILIFY

ARIPIPRAZOLE

Standard Dose
9.75MG/1.3ML (7.5MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: 901 REQUIRED Marketing status: Discontinued
Summary

Approval overview ABILIFY is listed in Drugs@FDA under application 021866 (NDA).

Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient ARIPIPRAZOLE Form and strength INJECTABLE;INTRAMUSCULAR - 9.75MG/1.3ML (7.5MG/ML) Sponsor OTSUKA Submission history Latest submission status date: 2020-02-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABILIFY is listed in Drugs@FDA under application 021866 (NDA). Review priority: 901 REQUIRED Marketing status: Discontinued Active ingredient ARIPIPRAZOLE Form and strength INJECTABLE;INTRAMUSCULAR - 9.75MG/1.3ML (7.5MG/ML) Sponsor OTSUKA Submission history Latest submission status date: 2020-02-05 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: 901 REQUIRED

Interaction Notes

  • No interaction notes stored yet.